IFNAR1 and peeling skin syndrome: The antimalarial hydroxychloroquine that is frequently used for treatment of pSS and SLE has similarly been described to prevent HKCA-induced training (51), providing a rationale for combination treatment of anti-IFNAR and hydroxychloroquine.